WalMart Ceo warns of Serious Inflation Months Ahead ...
Uploaded by RestoreConstitution8 on Jan 30, 2012
Walmart CEO confirms the rises prices!
Companies nearing the end of the FDA path
There is a nice-sized list of Bay Area companies nearing the end (presumably) of the FDA path toward approval. Among them:
WARREN BUFFET SAID ...
Pending FDA Drug Approval Decisions:
Jan. 27: Amylin Pharmaceuticals'(AMLN_) Bydureon for diabetes.
Feb. 14: BioSante Pharmaceuticals'(BPAX_) Bio-T-Gel for hypogonadism.
Feb. 17: Corcept Therapeutics'(CORT_) Corlux for Cushing's sydrome.
Feb. 26: Columbia Labs'(CBRX_) Prochieve for reduction of risk of preterm birth.
March 6: Discovery Labs'(DSCO_) Surfaxin for respiratory distress syndrome.
March 6: Astex Pharmaceuticals'(ASTX_) Dacogen for acute myeloid leukemia.
March 7: Neurogesx'(NGSX_) Qutenza for HIV-related nerve pain.
March 8: Roche and Curis'(CRIS_) vismodegib for basal cell carcinoma.
March 26: MAP Pharmaceuticals'(MAPP_) Levadex for migraines.
March 27: Affymax's(AFFY_) peginesatide for anemia due to chronic kidney disease.
March 28: Chelsea Therapeutics'(CHTP_) Northera for orthostatic hypotension.
April 17: Vivus'(VVUS_) Qnexa for obesity.
April 18: Vertex Pharmaceuticals'(VRTX_) Kalydeco for cystic fibrosis
April 24: Cell Therapeutics'(CTIC_) pixantrone for non-Hodgkin's lymphoma
April 26: Amgen's(AMGN_) Xgeva for prevention or delay of spread of prostate cancer to bone.
April 27: Vivus'(VVUS) avanafil for erectile dysfunction.
WARREN BUFFET SAID ...
- Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) of Mountain View — Feb. 4 approval date for Adasuve for agitation in patients with schizophrenia;
- NeurogesX Inc. (NASDAQ: NGSX) of San Mateo — Feb. 9 FDA panel for Qutenza in HIV-related pain where the nerves don’t work properly. NeurogesX also is looking at a March 7 FDA approval date for Qutenza;
- Corcept Therapeutics Inc. (NASDAQ: CORT) of Mountain View — Feb. 17 approval date for the Cushing’s Symdrome treatment Corlux;
- Vivus Inc. (NASDAQ: VVUS) of Mountain View — Feb. 22 FDA advisory panel for Qnexa for obesity;
- Genentech Inc. of South San Francisco and Curis Inc. (NASDAQ: CRIS) of Lexington, Mass. — March 8 approval date for vismodegib, a treatment for advanced basal cell carcinoma;
- MAP Pharmaceuticals Inc. (NASDAQ: MAPP) of Mountain View — March 26 approval date for Levadex in migraines;
- Affymax Inc. (NASDAQ: AFFY) of Palo Alto — March 27 approval date for peginesatide for anemia in kidney dialysis patients.
Pending FDA Drug Approval Decisions:
Jan. 27: Amylin Pharmaceuticals'(AMLN_) Bydureon for diabetes.
Feb. 14: BioSante Pharmaceuticals'(BPAX_) Bio-T-Gel for hypogonadism.
Feb. 17: Corcept Therapeutics'(CORT_) Corlux for Cushing's sydrome.
Feb. 26: Columbia Labs'(CBRX_) Prochieve for reduction of risk of preterm birth.
March 6: Discovery Labs'(DSCO_) Surfaxin for respiratory distress syndrome.
March 6: Astex Pharmaceuticals'(ASTX_) Dacogen for acute myeloid leukemia.
March 7: Neurogesx'(NGSX_) Qutenza for HIV-related nerve pain.
March 8: Roche and Curis'(CRIS_) vismodegib for basal cell carcinoma.
March 26: MAP Pharmaceuticals'(MAPP_) Levadex for migraines.
March 27: Affymax's(AFFY_) peginesatide for anemia due to chronic kidney disease.
March 28: Chelsea Therapeutics'(CHTP_) Northera for orthostatic hypotension.
April 17: Vivus'(VVUS_) Qnexa for obesity.
April 18: Vertex Pharmaceuticals'(VRTX_) Kalydeco for cystic fibrosis
April 24: Cell Therapeutics'(CTIC_) pixantrone for non-Hodgkin's lymphoma
April 26: Amgen's(AMGN_) Xgeva for prevention or delay of spread of prostate cancer to bone.
April 27: Vivus'(VVUS) avanafil for erectile dysfunction.
High Probability of Banking Crisis in 2012 ...?
David McAlvany: Mcalvany finacial companies CEO
Uploaded by LeakSourceArchive on Jan 14, 2012
Uploaded by LeakSourceArchive on Jan 14, 2012
01/03/2012
http://LeakSource.wordpress.com
http://LeakSource.wordpress.com
Subscribe to:
Posts (Atom)